APVO experienced a dramatic 75% revenue decline from $12.3M to $3.1M while simultaneously raising significant capital, boosting cash reserves by 148% and stockholders' equity by 266%.
The massive revenue drop signals potential setbacks in the company's commercial operations or clinical programs, which is concerning for a biotech company. However, the substantial increase in cash and equity suggests successful fundraising that should provide runway to navigate current challenges and continue development of their expanded 8-molecule pipeline.
APVO's financial profile shows a tale of two narratives - operational struggle and capital strength. Revenue collapsed 75% while cash more than doubled to $21.6M and stockholders' equity surged 266% to $17.4M, indicating successful equity fundraising. The 244% inventory increase alongside minimal capex spending suggests the company is building manufacturing capabilities while conserving cash, positioning for future growth despite current revenue headwinds.
Equity base grew 265.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Inventory surged 243.9% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.
Cash position surged 148.1% — strong cash generation or capital raise providing significant financial cushion.
Current assets grew 116.5% — improving short-term liquidity or inventory/receivables build.
Capex reduced 95.9% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Revenue declined 74.7% — significant demand weakness or market share loss warrants investigation.
Asset base grew 74.4% — expansion through organic growth, acquisitions, or capital deployment.
Receivables surged 34.5% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →